Osteoblast function in myeloma

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Multiple myeloma (MM) is the most frequent cancer to involve the skeleton and results in purely osteolytic lesions that rarely heal. MM bone disease is responsible for some of the most devastating complications of MM. The marrow microenvironment plays a key role in MM bone disease as well as in the initiation, expansion and chemoresistance of MM cells. How this microenvironment becomes so supportive of MM, and the contribution and interaction of the various components of the microenvironment to enhancing MM growth are only beginning to be understood. However, it is clear that suppression of osteoblast activity plays a key role in the bone destructive process as well as progression of the tumor burden in myeloma. The impairment of osteoblast activity in MM results primarily from blockade of osteogenic differentiation of mesenchymal progenitors to mature osteoblasts. MM patients have low to normal levels of bone formation markers, such as alkaline phosphatase and osteocalcin in the setting of increased bone resorption. In contrast, MM patients without bone lesions display balanced bone remodeling with increased osteoclastogenesis and normal or increased bone formation rates. Both soluble factors and cell-to-cell contact between MM cells and osteoblast progenitors are responsible for the suppression of osteoblast differentiation in MM. In this article, the mechanism responsible for osteoblast suppression will be reviewed, and the effects of novel bone anabolic agents on myeloma bone disease will be discussed.

Original languageEnglish (US)
Pages (from-to)135-140
Number of pages6
JournalBone
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Osteoblasts
Multiple Myeloma
Bone Diseases
Osteogenesis
Bone and Bones
Anabolic Agents
Bone Remodeling
Osteocalcin
Bone Resorption
Tumor Burden
Skeleton
Alkaline Phosphatase
Stem Cells
Bone Marrow

Keywords

  • Bone disease
  • Cancer
  • Multiple myeloma
  • Osteoblast
  • Osteoclast

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Osteoblast function in myeloma. / Roodman, G. David.

In: Bone, Vol. 48, No. 1, 01.01.2011, p. 135-140.

Research output: Contribution to journalArticle

Roodman, G. David. / Osteoblast function in myeloma. In: Bone. 2011 ; Vol. 48, No. 1. pp. 135-140.
@article{4276e6cef7484428bc633bc046c7f957,
title = "Osteoblast function in myeloma",
abstract = "Multiple myeloma (MM) is the most frequent cancer to involve the skeleton and results in purely osteolytic lesions that rarely heal. MM bone disease is responsible for some of the most devastating complications of MM. The marrow microenvironment plays a key role in MM bone disease as well as in the initiation, expansion and chemoresistance of MM cells. How this microenvironment becomes so supportive of MM, and the contribution and interaction of the various components of the microenvironment to enhancing MM growth are only beginning to be understood. However, it is clear that suppression of osteoblast activity plays a key role in the bone destructive process as well as progression of the tumor burden in myeloma. The impairment of osteoblast activity in MM results primarily from blockade of osteogenic differentiation of mesenchymal progenitors to mature osteoblasts. MM patients have low to normal levels of bone formation markers, such as alkaline phosphatase and osteocalcin in the setting of increased bone resorption. In contrast, MM patients without bone lesions display balanced bone remodeling with increased osteoclastogenesis and normal or increased bone formation rates. Both soluble factors and cell-to-cell contact between MM cells and osteoblast progenitors are responsible for the suppression of osteoblast differentiation in MM. In this article, the mechanism responsible for osteoblast suppression will be reviewed, and the effects of novel bone anabolic agents on myeloma bone disease will be discussed.",
keywords = "Bone disease, Cancer, Multiple myeloma, Osteoblast, Osteoclast",
author = "Roodman, {G. David}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.bone.2010.06.016",
language = "English (US)",
volume = "48",
pages = "135--140",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Osteoblast function in myeloma

AU - Roodman, G. David

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Multiple myeloma (MM) is the most frequent cancer to involve the skeleton and results in purely osteolytic lesions that rarely heal. MM bone disease is responsible for some of the most devastating complications of MM. The marrow microenvironment plays a key role in MM bone disease as well as in the initiation, expansion and chemoresistance of MM cells. How this microenvironment becomes so supportive of MM, and the contribution and interaction of the various components of the microenvironment to enhancing MM growth are only beginning to be understood. However, it is clear that suppression of osteoblast activity plays a key role in the bone destructive process as well as progression of the tumor burden in myeloma. The impairment of osteoblast activity in MM results primarily from blockade of osteogenic differentiation of mesenchymal progenitors to mature osteoblasts. MM patients have low to normal levels of bone formation markers, such as alkaline phosphatase and osteocalcin in the setting of increased bone resorption. In contrast, MM patients without bone lesions display balanced bone remodeling with increased osteoclastogenesis and normal or increased bone formation rates. Both soluble factors and cell-to-cell contact between MM cells and osteoblast progenitors are responsible for the suppression of osteoblast differentiation in MM. In this article, the mechanism responsible for osteoblast suppression will be reviewed, and the effects of novel bone anabolic agents on myeloma bone disease will be discussed.

AB - Multiple myeloma (MM) is the most frequent cancer to involve the skeleton and results in purely osteolytic lesions that rarely heal. MM bone disease is responsible for some of the most devastating complications of MM. The marrow microenvironment plays a key role in MM bone disease as well as in the initiation, expansion and chemoresistance of MM cells. How this microenvironment becomes so supportive of MM, and the contribution and interaction of the various components of the microenvironment to enhancing MM growth are only beginning to be understood. However, it is clear that suppression of osteoblast activity plays a key role in the bone destructive process as well as progression of the tumor burden in myeloma. The impairment of osteoblast activity in MM results primarily from blockade of osteogenic differentiation of mesenchymal progenitors to mature osteoblasts. MM patients have low to normal levels of bone formation markers, such as alkaline phosphatase and osteocalcin in the setting of increased bone resorption. In contrast, MM patients without bone lesions display balanced bone remodeling with increased osteoclastogenesis and normal or increased bone formation rates. Both soluble factors and cell-to-cell contact between MM cells and osteoblast progenitors are responsible for the suppression of osteoblast differentiation in MM. In this article, the mechanism responsible for osteoblast suppression will be reviewed, and the effects of novel bone anabolic agents on myeloma bone disease will be discussed.

KW - Bone disease

KW - Cancer

KW - Multiple myeloma

KW - Osteoblast

KW - Osteoclast

UR - http://www.scopus.com/inward/record.url?scp=78650417743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650417743&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2010.06.016

DO - 10.1016/j.bone.2010.06.016

M3 - Article

C2 - 20601285

AN - SCOPUS:78650417743

VL - 48

SP - 135

EP - 140

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -